<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430661</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076-103</org_study_id>
    <nct_id>NCT03430661</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel or Prasugrel in Healthy Subjects</brief_title>
  <official_title>Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel / Prasugrel), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or Prasugrel When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacodynamic (PD) effects of
      clopidogrel and prasugrel when administered after a single subcutaneous (s.c.) dose of
      ACT-246475 in healthy male and female subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched comparisons of %IPA (MPA) between treatments (i.e., Treatment A1 vs A2 and Treatment B1 vs B2, treatments are defined below) following administration of ACT-246475 and its matching placebo.</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>- %IPA[MPA] will be calculated as mean change in percentage from baseline for each time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-matched comparisons of %IPA (PRU) between treatments (i.e., Treatment A1 vs A2 and Treatment B1 vs B2) following administration of ACT-246475 and its matching placebo.</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>- %IPA[PRU] will be calculated as mean change in percentage from baseline for each time point.
Treatment A1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of clopidogrel (600 mg).
Treatment A2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of clopidogrel (600 mg).
Treatment B1: single s.c. dose administration of ACT-246475-matching placebo followed by a single oral dose of prasugrel (60 mg).
Treatment B2: single s.c. dose administration (16 mg) of ACT-246475 followed by a single oral dose of prasugrel (60 mg).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of clopidogrel (600 mg) given 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of clopidogrel (600 mg) given &gt;= 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of clopidogrel (600 mg) given &gt;= 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of prasugrel (60 mg) given 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of prasugrel (60 mg) given &gt;= 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of prasugrel (60 mg) given &gt;= 0.5 hours after single s.c. dose of ACT-246475 (16 mg) or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-246475</intervention_name>
    <description>Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Tablet for oral administration (600 mg)</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Tablet for oral administration (60 mg)</description>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part A: Group 3</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Signed informed consent

          -  Healthy male and female subjects aged between 18 and 65 years (inclusive) at screening

          -  Body mass index of 18.0 to 31.0 kg/m2 (inclusive) at Screening

          -  Women of childbearing potential must have a negative serum pregnancy test and use
             reliable birth controls from screening up to at least 30 days after last study
             treatment administration

          -  Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,
             and pulse rate 50-90 beats per minute (bpm) (inclusive) at screening

          -  Healthy on the basis of physical examination, cardiovascular assessments, and
             laboratory tests

          -  Maximum (at peak) platelet aggregation ≥ 40% (light transmission aggregometry [LTA])
             upon 20 μM adenosine diphosphate (ADP) activation at screening

          -  Values of closure time tested with the Platelet Function Analyzer (PFA) equipment, for
             both cartridges of collagen/adrenaline and collagen/ADP below the upper limit of
             normal range at screening

        Main Exclusion Criteria:

          -  Pregnant or lactating women

          -  Known hypersensitivity to ACT-246475, clopidogrel, prasugrel, any of their excipients,
             or drugs of the same class

          -  Any contraindication to clopidogrel and prasugrel treatment

          -  Known hypersensitivity or allergy to natural rubber latex

          -  Platelet count &lt; 120 × 109 L−1 at Screening and Day -1

          -  Known platelet disorders (e.g., Glanzmann thromboasthenia, von Willebrand disease,
             platelet release defect)

          -  Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs, P2Y12
             receptor antagonists, or any medication with blood-thinning activity (i.e., injectable
             or oral anticoagulants) within 3 weeks prior to study treatment administration

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Ufer, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CTD ClinicaL Trial Disclosure desk</last_name>
    <phone>+41 58 844 00 00</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotrial Inc</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principak Investigator</last_name>
      <phone>973-388-2848</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

